Navigation Links
Clinical studies show REMICADE reduces incidence of bowel surgeries in ulcerative colitis patients
Date:10/15/2007

< 0.05).

"These diseases are devastating to patients and their loved ones and we are excited to see more and better therapies become available to ease their suffering," said Richard J. Geswell, President, Crohn's & Colitis Foundation of America.

About the ACT Long-Term Extension

Patients with moderate to severe UC, defined as a baseline Mayo score 6 and 12, who were unresponsive to or intolerant to at least one standard therapy, including corticosteroids, immunosuppressants or 5ASAs, were enrolled in ACT 1 (n=364) or ACT 2 (n=364). The 728 patients were randomized to receive REMICADE 5 mg/kg, REMICADE 10 mg/kg or placebo at weeks 0, 2, 6 and every subsequent 8 weeks through week 22 (ACT 2) or week 46 (ACT 1). Patients were allowed to continue to receive conventional therapy.

Patients who completed treatment through the final infusion visit and who, in the opinion of the investigator, could benefit from continued treatment with REMICADE could enroll in the extension trials. Across multiple sites, one hundred and eighteen (118) patients were entered into the ACT 1 extension and 111 patients were entered into the ACT 2 extension.

During the extension, patients continued to receive the study drug to which they were originally randomized (REMICADE 5 mg/kg, REMICADE 10 mg/kg or placebo) every 8 weeks. Patients in the extension trials were assessed using the Physicians Global Assessment (PGA), which is 1 of 4 measures of disease activity included in the Mayo score. Of the 229 patients who entered the extension, 181 have been followed through one year, and 92 have completed two years. Patients who had responded to placebo also enrolled in

the extension to maintain the blind and continued to receive placebo every 8 weeks.

Overall, REMICADE was generally well tolerated in the long-term extensions, with less than five percent of patients discontinuing therapy due to an adverse event (AE). As previously rep
'/>"/>

Contact: Melissa Katz
215-325-6875
Centocor, Inc.
Source:Eurekalert

Page: 1 2 3 4 5 6

Related biology news :

1. Roche clinical trial registry and results database launched
2. NIAID begins clinical trial of West Nile virus vaccine
3. Compound might defeat African sleeping sickness, clinical trial beginning this month
4. Neurologix announces positive results of gene therapy clinical trial in Parkinsons disease
5. Dalai Lama, top scientists to discuss science & clinical applications of meditation
6. Stem cells electric abilities might help their safe clinical use
7. Clinical trial to test stem cell approach for children with brain injury
8. New malaria vaccine shows promise in early clinical trial
9. Preclinical study of a new brain tumor therapy
10. Tramiprosate (Alzhemed? preclinical results published in Neurobiology of Aging
11. Fatty spheres loaded with siRNA shrink ovarian cancer tumors in preclinical trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... engineers have devised a new implantable tissue scaffold coated ... a few weeks. When applied to bone injuries or ... form new bone that looks and behaves just like ... could offer a dramatic improvement over the current standard ... another part of the patient,s body a painful ...
(Date:8/19/2014)... infants born with neonatal abstinence syndrome (NAS) secondary ... time going through withdrawal than others, but the ... and epigenetic (when genes are turned on or ... factors, researchers at Boston University School of Medicine ... first of its kind study to identify some ...
(Date:8/19/2014)... of today,s crocodiles colonised the seas during warm phases ... new Anglo-French study which establishes a link between marine ... a period of more than 140 million years. ... the Universit de Lyon, France and formerly from the ... Nature Communications ., Today, crocodiles are ,cold-blooded, animals ...
Breaking Biology News(10 mins):Engineering new bone growth 2Engineering new bone growth 3In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2Evolution of marine crocodilians constrained by ocean temperatures 2
... Management District (SJRWMD) has contracted with Florida Tech scientists ... regarding the fish larvae and eggs (ichthyoplankton) that inhabit ... a comprehensive SJRWMD effort to address public concern regarding ... St. Johns River. One measure of the ...
... developed the first small molecule that can reversibly activate ... the way for drugs that can treat low blood ... sodium channel (ENaC) controls sodium flow across many tissues ... is vital to maintaining proper salt balance and blood ...
... the fundamental laws of the universe, science is still ... about the meaning of life, the existence of God ... Is that because science is not sufficiently advanced to ... approach to science is incapable of answering humanitys deepest ...
Cached Biology News:Grant to fund answers about St. Johns River 2Finding God with biocomplexity 2Finding God with biocomplexity 3
(Date:8/18/2014)... Fla. , Aug. 18, 2014 TNI ... biotechnology company pioneering the manufacturing and marketing of innovative ... that the Company is providing a second notice of ... In making the announcement, Noreen Griffin , ... you in advance for your participation in the Annual ...
(Date:8/18/2014)... 18, 2014 China is increasingly ... the clinical research industry. Clinicaltrial.gov statistics highlight the ... its aging population; a high increase in infectious ... densely populated pool of patients and a track ... positive points, China also presents challenges for the ...
(Date:8/16/2014)... 2014 Firms in the ... and advisory services to businesses, government bodies and ... services are highly diverse as operators assist a ... from geological and geophysical consulting services to risk ... past five years, the recovery of the Canadian ...
(Date:8/16/2014)... have found a way to make atomic-force microscope probes ... as small as the weight of an individual virus. ... National University (ANU), hinges on using laser beams to ... , "The level of sensitivity achieved after cooling is ... a large virus that is 100 billion times lighter ...
Breaking Biology Technology:TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 2TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 3TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 4China – Land of Opportunities & Challenges for the Clinical Research Industry, New Webinar Hosted by Xtalks 2Scientific and Economic Consulting in Canada Industry Market Research Report Now Available from IBISWorld 2Scientific and Economic Consulting in Canada Industry Market Research Report Now Available from IBISWorld 3Laser makes microscopes way cooler 2
... Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ), ... from Merz Pharmaceuticals GmbH (Merz) for sales,by ... for the treatment of,moderate-to-severe Alzheimer,s disease during ... exclusive marketing agreement, NTI currently receives,quarterly royalty ...
... evaluation of Botaneco,s technology to add ... functionality to Echium oil ... TSX symbol: SBS, CALGARY, April 30 ... has signed a,feasibility agreement with Croda Enterprise Technology, part of Croda,International Plc, an ...
... /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: AEZS , ... therapy and oncology, today announced that Prof. Frans ... Men,s Health Institutes,in The Netherlands, won the award ... the 23rd Annual European Association of Urology Meeting, ...
Cached Biology Technology:Botaneco signs feasibility agreement with Croda to develop specialty crop oil formulation 2Botaneco signs feasibility agreement with Croda to develop specialty crop oil formulation 3AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 2AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 3AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 4AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 5AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 6
Recombinant Feline IFN-alpha...
Rat monoclonal [HEK/1/85a] to CCR5 ( Abpromise for all tested applications). entrezGeneID: 1234 SwissProtID: P51681...
Mouse monoclonal [CAT-1] to Chloramphenicol Acetyltransferase ( Abpromise for all tested applications)....
...
Biology Products: